Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tamsulosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 10/20 | 1.00 |
| ▸ | ADRA1D known ✓ | P25100 | 9/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 9/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 4/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tamsulosin SCHEMBL34378 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL30361066 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL3343160 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL29599595 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL29363851 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL30465862 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL29588704 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL29566149 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL1560198 | 0.99 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL2315085 | 0.99 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109824569-A | A kind of (R)-5-(2-(2-(2-ethoxyphenoxy)ethylamino)propyl)-2-methoxybenzensulfonamide crystal form I and preparation method thereof | 重庆医药高等专科学校 | 2019-05-31 | — | — | CN | claimed |
| EP-3452016-A1 | DELAYED RELEASE ORAL TAMSULOSIN HYDROCHLORIDE | Aspen Park Pharmaceuticals Inc. (US) | 2019-03-13 | — | — | EP | claimed |
| WO-2017192808-A1 | DELAYED RELEASE ORAL TAMSULOSIN HYDROCHLORIDE | ASPEN PARK PHARMACEUTICALS, INC. (US) | 2017-11-09 | — | — | WO | claimed |
| US-20170231974-A1 | Combined Use of an Alpha-Adrenergic Receptor Antagonist and an Anti-Muscarinic Agent | ASTELLAS IRELAND CO., LTD. (IE) | 2017-08-17 | — | — | US | claimed |
| EP-1786764-B1 | PROCESS FOR PREPARING TAMSULOSIN | SCINOPHARM SINGAPORE PTE LTD (SG) | 2017-03-15 | — | — | EP | claimed |
| CN-102579359-B | A kind of Tamsulosin sustained release pellet and preparation method thereof | 北京科信必成医药科技发展有限公司 | 2016-07-06 | — | — | CN | claimed |
| CN-105457038-A | Quick release type medicine phosphatide compound and medicine composition thereof | UNIV SOUTHEAST | 2016-04-06 | — | — | CN | claimed |
| CN-102145003-B | Medicinal composition containing insoluble medicament | ZHANG LIYING | 2015-04-22 | — | — | CN | claimed |
| CN-103848772-A | Preparation method of important intermediate of Silodosin | STONE LAKE PHARMA TECH CO LTD | 2014-06-11 | — | — | CN | claimed |
| US-20130267557-A1 | Combined Use of an Alpha-Adrenergic Receptor Antagonist and an Anti-Muscarinic Agent | ASTELLAS IRELAND CO., LTD. (IE) | 2013-10-10 | — | — | US | claimed |
| US-5288759-A | Topical; comfortable to eye | ALCON LABORATORIES, INC. (US) | 1994-02-22 | — | — | US | claimed |
| EP-0416804-B1 | EXTERNAL PREPARATION CONTAINING AMUSULOSIN | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1993-05-26 | — | — | EP | claimed |
| EP-0439320-A1 | Erectile dysfunction treatment | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1991-07-31 | — | — | EP | claimed |
| EP-0416804-A1 | External preparation containing amusulosin | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1991-03-13 | — | — | EP | claimed |
| US-4761500-A | CONGESTIVE HEART FAILURE | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1988-08-02 | — | — | US | claimed |
| US-4731478-A | ADRENERGIC BLOCKING AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1988-03-15 | — | — | US | claimed |
| US-4703063-A | TAMSULOSIN HYDROCHLORIDE; antihypertensive agent and an agent for the treatment of congestive heart failure | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1987-10-27 | — | — | US | claimed |
| EP-0034432-B1 | SULFAMOYL-SUBSTITUTED PHENETHYLAMINE DERIVATIVES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS, CONTAINING THEM | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1984-04-25 | — | — | EP | claimed |
| US-4373106-A | Sulfamoyl-substituted phenethylamine derivatives and process of producing them | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1983-02-08 | — | — | US | claimed |
| EP-0034432-A2 | Sulfamoyl-substituted phenethylamine derivatives, their preparation, and pharmaceutical compositions, containing them | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1981-08-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267557-A1 | Combined Use of an Alpha-Adrenergic Receptor Antagonist and an Anti-Muscarinic Agent | ADRB1, ADRB2, ADRB3 | ADRA1A 4/4885ADRA1D 6/4885ADRA1B 5/4885 |
| US-20170231974-A1 | Combined Use of an Alpha-Adrenergic Receptor Antagonist and an Anti-Muscarinic Agent | ADRB1, ADRB2, ADRB3 | ADRA1A 4/4885ADRA1D 6/4885ADRA1B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.